Why Sellas Life Sciences Group Inc. (SLS) Stock Fell 2.1% on Nov 13, 2026
as of yesterday, 9:52 AM ET
The reason we found
SELLAS Advances Toward Transformative AML Trial Results
SELLAS said topline primary-endpoint results from its Phase 3 REGAL trial in acute myeloid leukemia are expected this month, creating a significant near-term catalyst. The company also reported $134.7 million in cash, supporting operations while investors await potentially important clinical data.
clinical trial catalysthigh confidence
Sources 7
- SELLAS Life Sciences Gr Q3 EPS $(0.05), Inlinefinnhub.io
- 12 Health Care Stocks Moving In Friday's Pre-Market Sessionfinnhub.io
- SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Monthfinnhub.io
- SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updatemanilatimes.net
- SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updatefinance.yahoo.com
- SELLAS Life Sciences Group, Inc. (SLS) Stock Price, News, Quote & History - Yahoo! Finance Canadanews.google.com
- SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updatefinnhub.io
Our call
Buy moredated Nov 13, 2026
Sellas Life Sciences fell 6.5% over the past five trading days while other health care stocks rose 1.1%, but analysts expect profit to grow 54% next year. We'd stop buying if Sellas Life Sciences' next report misses profit forecasts.
Other moves on Nov 13
- SPCE−31.1%Virgin Galactic tumbles on financing plans and delayed flights
- MOD+27.9%Samsung Acquisition Talks Send Modine Shares Surging
- TNDM+14.5%Health Canada Expands Tandem’s Insulin Pump Approvals
- NU+11.7%Nu Holdings jumps after record profit and strong Q3 growth
- CBRS+11.1%Strong earnings and Microsoft deal lift Cerebras shares
- NBIS−10.0%Nebius selloff reflects higher spending and weaker near-term outlook